samedan logo
 
 
 
spacer
home > ebr > summer 2019 > leveraging novel therapeutics and diagnostic assays
PUBLICATIONS
European Biopharmaceutical Review

Leveraging Novel Therapeutics and Diagnostic Assays

Immunotherapy is far from a novel concept, and its history is intriguing. It all began in 1891 when Dr William B Coley attempted to creatively harness the patientís immune system. William achieved durable complete remission in several types of malignancies to include sarcoma, lymphoma, and testicular carcinoma by injecting mixtures of live and attenuated bacteria into patientsí tumours. Needless to say, we have come a long way.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marisa Pearce is Scientific Affairs Liaison at Molecular MD, an ICON company, and has over 10 years of experience in oncology biomarker test development. She has been involved in the planning and design of molecular tests across the continuum from translational research to clinical deployment. These efforts include research use only assays for solid tumour profiling to the commercialisation of companion diagnostics for minimal residual disease monitoring. Marisa's diverse background enables her to serve as subject matter expert on the selection and use of a variety of technologies for biomarker assay development. At MolecularMD, an ICON plc company, biopharma clients have access to a fit-for-purpose, platform-agnostic approach leveraging technology platforms such as NGS, droplet digital PCR, and multiplexed IHC for the codevelopment of clinical trial assays and/or downstream diagnostics aligned with the therapeutic program objectives.
spacer
Marisa Pearce
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinerion adds Patient Network Explorer Coverage to three new Hospitals in Brazil

Basel, Switzerland, April 19th, 2022: Clinerion has extended its patient coverage in Brazil to three new hospitals with the help of partner iHealth Group. This raises the footprint of Clinerionís Patient Network Explorer to 22 healthcare organisations and over 8 million patients in Brazil.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement